Literature DB >> 29029237

CPAP Does Not Reduce Inflammatory Biomarkers in Patients With Coronary Artery Disease and Nonsleepy Obstructive Sleep Apnea: A Randomized Controlled Trial.

Erik Thunström1, Helena Glantz1,2, Tülay Yucel-Lindberg3, Kristin Lindberg3, Mustafa Saygin4, Yüksel Peker1,5.   

Abstract

Objectives: Obstructive sleep apnea (OSA) and enhanced vascular inflammation coexist in patients with coronary artery disease (CAD). Continuous positive airway pressure (CPAP) is first-line treatment for OSA with daytime sleepiness. This analysis of data from the RICCADSA (Randomized Intervention with CPAP in Coronary Artery Disease and Sleep Apnea) trial investigated the effects of CPAP on inflammatory markers in patients with CAD and nonsleepy OSA.
Methods: This single-center, randomized, controlled, open-label trial enrolled consecutive revascularized patients with nonsleepy OSA (apnea-hypopnea index >15/h; Epworth Sleepiness Scale score <10). Levels of high-sensitivity C-reactive protein (hs-CRP), interleukin (IL)-6, IL-8, and tumor necrosis factor-α (TNF-α) were measured in blood samples taken at baseline (median 94 days after revascularization) and after 1 year of follow-up in patients randomized to CPAP or no-CPAP.
Results: A total of 220 patients with analyzable blood samples at baseline and 1 year were included. Baseline IL-6 levels were significantly lower in the CPAP versus no-CPAP group (median 3.1 pmol/L [interquartile range 1.3-5.7] vs. 4.2 pmol/L [2.0-8.9], respectively; p = .005). At 1-year follow-up, median IL-6 levels were significantly reduced in both groups (to 2.2 pmol/L [1.2-3.9] in the CPAP group and to 2.2 [1.2-4.7] in no-CPAP group; both p < .001 vs. baseline). IL-8, hs-CRP, and TNF-α did not change significantly from baseline. There was no association between CPAP adherence and changes in inflammatory marker levels. Conclusions: In patients with stable CAD and nonsleepy OSA, inflammatory biomarkers did not change significantly over time except for IL-6 levels, which reduced to the same extent in the CPAP and no-CPAP groups. Clinical Trial Registration: ClinicalTrials.gov, ID: NCT00519597; researchweb.org, VGSKAS-4731. © Sleep Research Society 2017. Published by Oxford University Press on behalf of the Sleep Research Society. All rights reserved. For permissions, please e-mail journals.permissions@oup.com.

Entities:  

Keywords:  continuous positive airway pressure; coronary artery disease; interleukin-6; interleukin-8; obstructive sleep apnea; tumor necrosis factor-α

Mesh:

Substances:

Year:  2017        PMID: 29029237     DOI: 10.1093/sleep/zsx157

Source DB:  PubMed          Journal:  Sleep        ISSN: 0161-8105            Impact factor:   5.849


  13 in total

1.  Obstructive sleep apnea and CPAP therapy alter distinct transcriptional programs in subcutaneous fat tissue.

Authors:  Sina A Gharib; Amanda L Hurley; Michael J Rosen; James C Spilsbury; Amy E Schell; Reena Mehra; Sanjay R Patel
Journal:  Sleep       Date:  2020-06-15       Impact factor: 5.849

Review 2.  Cardiovascular outcomes of continuous positive airway pressure therapy for obstructive sleep apnea.

Authors:  Yüksel Peker; Baran Balcan
Journal:  J Thorac Dis       Date:  2018-12       Impact factor: 2.895

Review 3.  Redesigning Care for OSA.

Authors:  Lucas M Donovan; Aditi Shah; Ching Li Chai-Coetzer; Ferran Barbé; Najib T Ayas; Vishesh K Kapur
Journal:  Chest       Date:  2019-10-19       Impact factor: 9.410

4.  Coronary computed tomography angiography-based assessment of vascular inflammation in patients with obstructive sleep apnoea and coronary artery disease.

Authors:  Jeremy Yuvaraj; William Cameron; Jordan Andrews; Andrew Lin; Nitesh Nerlekar; Stephen J Nicholls; Garun S Hamilton; Dennis T L Wong
Journal:  Cardiovasc Diagn Ther       Date:  2022-02

Review 5.  Epidemiology, Physiology and Clinical Approach to Sleepiness at the Wheel in OSA Patients: A Narrative Review.

Authors:  Maria R Bonsignore; Carolina Lombardi; Simone Lombardo; Francesco Fanfulla
Journal:  J Clin Med       Date:  2022-06-27       Impact factor: 4.964

Review 6.  Obstructive sleep apnea and the metabolic syndrome: The road to clinically-meaningful phenotyping, improved prognosis, and personalized treatment.

Authors:  Jordan Gaines; Alexandros N Vgontzas; Julio Fernandez-Mendoza; Edward O Bixler
Journal:  Sleep Med Rev       Date:  2018-09-03       Impact factor: 11.609

Review 7.  Obstructive sleep apnea and multiple facets of a neuroinflammatory response: a narrative review.

Authors:  Valentina Gnoni; Katarina Ilic; Panagis Drakatos; Marija M Petrinovic; Diana Cash; Joerg Steier; Mary J Morrell; Zdravko Petanjek; Svjetlana Kalanj-Bognar; Ivana Rosenzweig
Journal:  J Thorac Dis       Date:  2022-02       Impact factor: 2.895

Review 8.  The multisystemic effects of oral appliance therapy for obstructive sleep apnea: A narrative review.

Authors:  Hee Young Kim; Jung Hwan Jo; Jin Woo Chung; Ji Woon Park
Journal:  Medicine (Baltimore)       Date:  2022-07-22       Impact factor: 1.817

9.  Obstructive Sleep Apnea, Sleepiness, and Glycemic Control in Type 2 Diabetes.

Authors:  R Nisha Aurora; Naresh M Punjabi
Journal:  J Clin Sleep Med       Date:  2019-05-15       Impact factor: 4.062

Review 10.  Cardiovascular Disorders Triggered by Obstructive Sleep Apnea-A Focus on Endothelium and Blood Components.

Authors:  Jakub Mochol; Jakub Gawrys; Damian Gajecki; Ewa Szahidewicz-Krupska; Helena Martynowicz; Adrian Doroszko
Journal:  Int J Mol Sci       Date:  2021-05-12       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.